Datopotamab deruxtecan (Dato-DXd)

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

7mo

AZN.LPhase 2$217.4B

Datopotamab deruxtecan (Dato-DXd) Phase 2 Results Expected

Datopotamab deruxtecan (Dato-DXd)• Non-small Cell Lung Cancer (NSCLC)582

Aug 19

00%

Drug Information

Target Indication

Non-small Cell Lung Cancer (NSCLC)

Clinical Trial

Last updated: 1/17/2026

Developer

AZN.L

AstraZeneca PLC

Related Pipeline

Diabetes

Asthma

Non-small Cell Lung Cancer

Type 2 Diabetes Mellitus

Chronic Obstructive Pulmonary Disease (COPD)